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Abstract
Background: The presence of certain underlying medical conditions is known to increase the risk of pneumococcal
disease in persons of all ages and across a wide spectrum of conditions, as demonstrated in two recent evaluations.
Corresponding estimates of attributable economic costs have not been well characterized. We thus undertook a
retrospective evaluation to estimate rates and costs of pneumococcal disease among children and adults with and
without underlying medical conditions in the United States.
Methods: Data were obtained from three independent healthcare claims repositories. The study population
included all persons enrolled in participating health plans during 2007–2010, and was stratified into subgroups
based on age and risk profile: healthy; at-risk, due to selected comorbid conditions; and high-risk, due to selected
immunocompromising conditions. At-risk and high-risk conditions, as well as episodes of invasive pneumococcal
disease (IPD) and all-cause pneumonia (PNE), were identified via diagnosis, procedure, and drug codes. Rates and
healthcare costs of IPD and PNE (2010US$) among at-risk and high-risk persons were compared with those from
age-stratified healthy counterparts using incidence rate ratios (IRR) and cost ratios.
Results: Rates of IPD and PNE were consistently higher among at-risk persons (IRR = 4.1 [95 % CI 3.9–4.3] and
4.5 [4.49–4.53]) and high-risk persons (IRR = 10.3 [9.7–11.0] and 8.2 [8.2–8.3]) of all ages versus their healthy
counterparts. Rates were notably high for at-risk persons with ≥2 conditions (IRR = 9.0 [8.4–9.7] and 10.3 [10.3–10.4]), as
well as those with asthma (IRR = 3.4 [3.0–3.8] and 4.5 [4.47–4.53]) or diabetes (IRR = 4.3 [4.0–4.6] and 4.7 [4.6–4.7]).
Healthcare costs totaled $21.7 million per 100,000 at-risk person-years and $58.5 million per 100,000 high-risk
person-years, which were 8.7 [8.5–8.8] and 23.4 [22.9–23.8] times higher than corresponding costs for healthy persons.
Conclusions: Rates and costs of IPD and PNE are substantially higher among persons with certain chronic and
immunocompromising conditions versus those without any such conditions. Rates and costs for persons with asthma
and diabetes were especially increased, and rates and costs for individuals with ≥2 at-risk conditions approached those
among persons with high-risk conditions.
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Background
Streptococcus pneumoniae (pneumococcus) has long
been recognized as a major cause of serious but uncom-
mon invasive diseases such as meningitis and bacteremic
pneumonia, and much more common non-invasive dis-
eases such as non-bacteremic pneumonia and acute
otitis media. Not surprisingly then, the economic burden
of pneumococcal disease in the United States (US) has
been reported to be substantial. In one recent evaluation,
Huang and colleagues estimated the direct cost of
pneumococcal disease among persons of all ages in the
US to have been $3.5 billion in 2004 [1]. In another
evaluation, Weycker and colleagues estimated the direct
cost of pneumococcal disease among older US adults
(i.e., persons aged ≥ 50 years) to have been $3.7 billion in
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2007 [2]. Finally, Wroe and colleagues projected that
from 2004–2040, as the size of the US population grows
(especially the elderly) and absent intervention, the
number of hospitalizations for pneumococcal pneumo-
nia will nearly double and the total economic burden of
pneumococcal pneumonia will increase by $2.5 billion
annually [3].
In the study by Weycker et al., the effect of patients’
underlying risk of pneumococcal disease on both the
cost per case of disease and the overall economic burden
of pneumococcal disease were examined, but only to a
limited extent [2]. We therefore examined in greater
detail, and for persons of all ages, the clinical and
economic burden of pneumococcal disease in the US
in relation to underlying risk status. Risk profiles were
determined by the presence of selected underlying
chronic illnesses that are currently listed in guidelines
promulgated by the US Advisory Committee on
Immunization Practices (ACIP) as indications for
pneumococcal vaccination, as well as conditions that
might increase the risk of infection based on limited
data from other studies [4–7].
Methods
Study design
A retrospective cohort design was employed. Study co-
horts were identified at the beginning of each calendar
year of observation―from 2007 to 2010―and study
subjects were stratified in terms of age and the presence
of underlying medical conditions (i.e., risk profile) based
on information recorded at any time prior to January 1st
of that calendar year. For each cohort, episodes of inva-
sive pneumococcal disease (IPD) and all-cause pneumonia
(PNE) were ascertained during the 1-year period begin-
ning on January 1st of each corresponding year and ending
on December 31st of that year (or date of loss to follow-
up, if earlier). (All-cause PNE was selected as a study mea-
sure—rather than pneumococcal pneumonia—because
pneumococcal pneumonia is under-reported in healthcare
claims and ~30 % of all cause PNE is estimated to be due
to Streptococcus pneumoniae [7, 8]. Stratum-specific rates
of IPD and PNE (per 100,000 person-years) were esti-
mated over the entire study period. Subjects who met
criteria for inclusion in multiple calendar years contrib-
uted data to each cohort for which they were eligible.
Data source
Data were obtained from three large integrated health-
care claims repositories and spanned January 1, 2006
through December 31, 2010. The three databases—
Truven Health Analytics MarketScan® Commercial
Claims and Encounters and Medicare Supplemental and
Coordination of Benefits Databases, Intercontinental
Marketing Services’ (IMS) LifeLink™ PharMetrics Health
Plan Claims Database, and OPTUM Research Database—
include medical (i.e., facility and professional-service)
claims and outpatient pharmacy claims from private US
health plans. Together, these three geographically diverse
repositories capture healthcare claims information for >35
million plan members annually.
Data available from each facility and professional-
service claim included dates and places of service, diag-
noses (International Classification of Diseases, Ninth
Revision, Clinical Modification [ICD-9-CM]), procedures
performed/services rendered [ICD-9-CM, Healthcare
Common Procedure Coding System (HCPCS)], and
quantity of services (professional-service claims). Data
available for each outpatient pharmacy claim included
the drug dispensed, dispensing date, quantity dispensed,
and number of days supplied. Medical and pharmacy
claims also included amounts paid by health plans and
patients for services rendered, or standardized estimates
of the cost of services. In addition, selected demographic
and eligibility information (including age/year of birth,
sex, geographic region of residence, and dates of plan
eligibility) were available.
The study databases were de-identified prior to
their release to study investigators. The study data-
bases have been evaluated and certified by independ-
ent third parties to be in compliance with the Health
Insurance Portability and Accountability Act (HIPAA)
of 1996 statistical de-identification standards and to
satisfy the conditions set forth in Sections 164.514
(a)-(b)1ii of the HIPAA Privacy Rule regarding the deter-
mination and documentation of statistically de-identified
data. Use of the study databases for health services
research is therefore fully compliant with the HIPAA
Privacy Rule and federal guidance on Public Welfare and
the Protection of Human Subjects [9]. Permission to use
the data sources for analyses described herein was re-
quested by study investigators and was granted by the data
vendors. Detailed descriptions of the three healthcare
claims repositories are provided in the Additional file 1.
Study population
The study population comprised all persons of all ages
who were enrolled in participating health plans on the
first day of one or more calendar years from 2007 to
2010. Study subjects were stratified based on their age
(0–17, 18–64, and ≥65 years) and risk profile (“healthy”,
“at-risk”, and “high-risk”) as of the beginning of each
year. At-risk persons included those who were immuno-
competent with ≥1 chronic medical condition. High-risk
persons included those who were immunocompromised,
immunosuppressed, or had a cochlear implant. At-risk
and high-risk categories were mutually exclusive and
thus, for example, persons considered immunosup-
pressed because of cancer were included in the high-risk
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category only, even if they also had an at-risk condition.
Healthy persons included those without evidence of at-
risk or high-risk conditions.
The lists of at-risk and high-risk conditions included
all those set forth by the ACIP in its recommendations
for pneumococcal vaccination; the at-risk list also in-
cluded the following conditions: asthma, chronic ster-
oid use, trisomy 21, prematurity/low birth weight,
neuromuscular/seizures disorders, rheumatoid arthritis,
systemic lupus erythematosis, and Crohn’s disease [10].
At-risk and high-risk conditions were ascertained using
information (i.e., ICD-9-CM diagnosis codes, ICD-9-CM/
HCPCS procedure codes, and drug codes from the
HCPCS/National Drug Code [NDC] systems) re-
corded any time prior to the beginning of the study
year. Persons with at-risk conditions were stratified by
the number of conditions; those with asthma and diabetes
were further stratified by disease severity. Operational al-
gorithms that were employed to identify at-risk and high-
risk conditions are set forth in Additional file 1: Tables S1
and S2.
Persons who were not continuously eligible for com-
prehensive health (i.e., medical and drug) benefits for at
least 1 year prior to January 1st of ≥1 corresponding years
were excluded from the study population. Infants (i.e.,
those <12 months of age as of January 1st) in a given year,
were not subject to this exclusionary criterion.
Study measures
Study measures included episodes and associated health-
care costs of selected manifestations of pneumococcal
infection, including IPD and PNE. All-cause pneumonia
was chosen as an outcome measure in preference to
pneumococcal pneumonia because, although S. pneumo-
niae infection is recognized as the most common cause
of pneumonia, the diagnostic code for pneumococcal
pneumonia appears uncommonly in healthcare claims
data (due to the relatively small number of times S. pneu-
moniae is successfully cultured in clinical practice from
patients with pneumonia).
Episodes of IPD and PNE were ascertained beginning
on January 1st and ending on December 31st of each
study year (or the date of loss to follow-up, if prior to
December 31st). Disease episodes requiring inpatient
care were identified using operational algorithms based
on ICD-9-CM diagnosis codes, and spanned the dur-
ation of hospitalization. Episodes of IPD requiring
outpatient care only were identified based on ICD-9-CM
diagnosis codes and HCPCS/NDC codes for antibiotic
therapy (±5 days), while episodes of PNE requiring out-
patient care only were identified based on ICD-9-CM
diagnosis codes, CPT codes for chest x-ray, and HCPCS/
NDC codes for antibiotic therapy (±5 days); outpatient
episodes spanned a maximum of 90 days (Additional file 1:
Table S3). Multiple episodes during a given study year were
included if they were separated by at least 90 days.
A disease-attributable approach was used to estimate
healthcare costs whereby expenditures for disease-
related services rendered during the episode of care were
tallied. Disease-related services were identified based on
diagnosis codes (principal diagnosis only on inpatient
claims), procedure codes, and drug codes. The cost of
inpatient episodes included hospitalizations, ambulatory
visits, and pharmacotherapy during the episode; the cost
of outpatient episodes included all outpatient visits and
pharmacotherapy during the episode. Costs were esti-
mated using healthcare expenditures reported on claims
(i.e., amounts reimbursed to healthcare providers by
health plans and patients for services rendered), and
were expressed in 2010 US dollars.
Analyses
Crude analyses were undertaken to estimate rates of dis-
ease episodes (per 100,000 person-years) within each age
group by risk profile and individual risk condition, using
data from all three study repositories. Differences in
rates of disease—and corresponding 95 % confidence
intervals (CIs)—between at-risk/high-risk persons and
healthy counterparts were expressed as incidence rate
ratios (IRR) using Poisson regression analysis.
Mean episodic costs of IPD and PNE by age and risk
profile were estimated using data only from the Market-
Scan Database since it was the only source for which we
had access to detailed patient-level data. Costs of IPD
and PNE (per 100,000 person-years) by age and risk
profile—as well as corresponding differences and 95 %
CIs between risk groups—were estimated by combining
sampled rates of disease (from all three data sources)
and sampled age- and risk-specific unit costs (from
MarketScan) via techniques of non-parametric boot-
strapping (percentile method, 1000 replications with re-
placement). All analyses were conducted using SAS® 9.3
for Windows® (SAS Institute Inc., Cary, NC, USA).
Results
Risk profiles
Children (aged 0–17 years) who qualified for inclusion
in the study contributed a total of 26.5 million person-
years of observation (Table 1). Approximately 92 % of
children had none of the selected chronic or immuno-
compromising conditions, 8 % had ≥1 at-risk condition
(and no high-risk conditions), and <1 % had a high-risk
condition. Among children with at-risk conditions,
asthma (63 %), prematurity/low birth weight (13 %),
neuromuscular/seizure disorders (10 %), and chronic
lung disease (10 %) were the most common. Of children
with ≥1 at-risk condition, 7 % had ≥2 such conditions.
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Adults aged 18–64 years and ≥65 years contributed
79.9 million and 11.4 million person-years of observa-
tion, respectively. Approximately 79 % of adults aged
18–64 years had none of the selected chronic or immu-
nocompromising conditions, while 17 % had ≥1 at-risk
condition (and no high-risk conditions) and 4 % had a
high-risk condition. The most common conditions in
this age group were diabetes (43 %), chronic heart dis-
ease (23 %), and asthma (16 %); 18 % had ≥2 of any of
the listed at-risk conditions. The prevalence of at-risk
and high-risk conditions in persons aged ≥65 years was
39 % and 15 %, respectively; the most common condi-
tions were chronic heart disease (52 %), diabetes
(50 %), and chronic lung disease (19 %); 32 % had ≥2
such conditions.
Clinical and economic burden
Rates of IPD and PNE were consistently higher among
at-risk persons of all ages (IRR = 4.1 [95 % CI 3.9–4.3]
and 4.5 [4.49–4.53]) and high-risk persons of all ages
(IRR = 10.3 [9.7–11.0] and 8.2 [8.2–8.3]) versus their
healthy counterparts. Rates were notably high for at-risk
persons with ≥2 at-risk conditions (IRR = 9.0 [8.4–9.7] and
10.3 [10.3–10.4]), as well as those with asthma (IRR = 3.4
[3.0–3.8] and 4.5 [4.47–4.53]) or diabetes (IRR = 4.3
[4.0–4.6] and 4.7 [4.6–4.7]).
Cost per IPD episode was generally similar across risk
groups, while the cost per PNE episode was highest for
the high-risk population followed by the at-risk and
healthy populations (Table 2). Differences in economic
costs of IPD and PNE per 100,000 person-years, by risk
profile and number of at-risk conditions, were roughly
the same as those for disease rates (Figs. 1 and 2).
Although high-risk persons were a small proportion of
the total, they accounted for a substantial proportion of
total costs (Fig. 3). On an overall basis, high-risk persons
constituted only about 4 % of the population, but
accounted for 18 % of cases of IPD/PNE and 30 % of the
total cost of IPD/PNE. Similarly, persons with ≥2 at risk
conditions, while constituting only 3 % of the total
population, accounted for 21 % of total IPD/PNE costs.
Economic costs increased in a graded fashion by severity
Table 1 Rates of invasive pneumococcal disease and all-cause pneumonia among healthy, at risk, and high-risk persons
Invasive Pneumococcal Disease




















Healthy 24,406,759 63,445,448 5,389,930 2.5 – 2.7 – 8.3 –
At-Risk 2,002,374 13,368,935 4,579,505 5.9 2.4 (2.0–2.9) 9.3 3.4 (3.2–3.7) 23.0 2.8 (2.5–3.1)
Alcoholism 4591 333,634 23,905 0.0 – 20.4 7.5 (5.9–9.6) 41.8 5.0 (2.7–9.4)
Asthma 1,252,480 2,185,510 362,183 3.7 1.5 (1.1–2.0) 9.6 3.6 (3.1–4.1) 34.2 4.1 (3.4–5.0)
Chronic heart disease 136,206 3,082,998 2,363,798 13.9 5.7 (3.6–8.9) 11.5 4.3 (3.8–4.8) 26.6 3.2 (2.8–3.6)
Chronic liver disease 3759 292,697 50,540 26.6 10.8 (1.5–76.7) 24.6 9.1 (7.2–11.5) 53.4 6.4 (4.4–9.5)
Chronic lung disease 192,731 1,251,143 882,061 8.3 3.4 (2.0–5.5) 27.0 10.0 (8.9–11.2) 51.1 6.2 (5.4–7.0)
Chronic use of oral steroids 22,508 275,267 65,775 13.3 5.4 (1.7–16.8) 8.0 3.0 (1.9–4.5) 15.2 1.8 (1.0–3.4)
Diabetes 88,848 5,721,158 2,267,133 5.6 2.3 (0.9–5.5) 9.5 3.5 (3.2–3.9) 21.1 2.5 (2.2–2.9)
Down’s syndrome 20,657 7649 63 19.4 7.9 (2.9–21.0) 13.1 4.8 (0.7–34.4) 0.0 –
Neuromuscular/seizure disorders 193,657 507,134 104,864 11.9 4.8 (3.2–7.3) 12.8 4.7 (3.7–6.1) 38.1 4.6 (3.3–6.3)
Short gestation/low birthweight 249,576 34,580 90 12.0 4.9 (3.4–7.0) 5.8 2.1 (0.5–8.6) 0.0 –
Rheumatoid arthritis/Crohn’s/Lupus – 579,373 162,206 – – 17.8 6.6 (5.4–8.0) 33.3 4.0 (3.0–5.3)
Smokers 5019 2,128,945 180,504 0.0 – 12.5 4.6 (4.1–5.3) 34.9 4.2 (3.2–5.5)
High-Risk 119,692 3,062,400 1,774,181 48.5 19.6 (15.0–25.7) 26.3 9.7 (9.0–10.6) 36.7 4.4 (3.9–5.0)
Chronic renal failure 17,112 356,088 344,160 64.3 26.1 (14.4–47.3) 47.2 17.5 (14.9–20.5) 50.0 6.0 (5.0–7.2)
Cochlear implant 1989 2517 1144 50.3 20.4 (2.9–145.0) 0.0 – 87.4 10.5 (1.5–74.8)
Congenital immunodeficiency 21,047 76,771 14,392 42.8 17.3 (9.0–33.5) 87.3 32.3 (25.3–41.2) 118.1 14.2 (8.8–23.1)
Diseases of white blood cells 15,493 149,802 46,869 122.6 49.7 (31.5–78.5) 62.1 23.0 (18.6–28.3) 110.9 13.3 (10.0–17.8)
Functional/anatomic asplenia 19,321 109,298 42,976 119.0 48.3 (31.8–73.2) 93.3 34.5 (28.3–42.2) 116.3 14.0 (10.5–18.7)
HIV 1484 193,184 7306 0.0 – 46.6 17.2 (13.9–21.3) 27.4 3.3 (0.8–13.2)
Immuno. conditions/drugs 63,702 2,495,776 1,523,021 54.9 22.3 (15.8–31.3) 24.4 9.0 (8.2–9.9) 36.4 4.4 (3.9–5.0)
aRelative to healthy counterparts
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of asthma (Additional file 1: Figure S1) and diabetes
(Additional file 1: Figure S2).
Discussion
Our results, based on analyses of data from three large
repositories of healthcare claims, suggest that the in-
creased rates of pneumococcal disease associated with
certain comorbid conditions (i.e., among at-risk and
high-risk persons) are closely aligned with increased
healthcare costs in these populations. Elevated rates and
higher episodic costs of IPD and PNE in at-risk and
high-risk populations resulted in total healthcare costs
that were 3–43 times higher (per 100,000 person-
years)—depending on age and condition—compared
with age-stratified healthy counterparts. Among adults
aged 18–64 years, for example, the annual cost of PNE
(per 100,000 persons) increased from $1.8 million for
healthy persons, to $13.9 million for at-risk persons, and
to $50.4 million for high-risk persons. Underlying the
higher overall costs are increasing rates of disease (from
458, to 1652, to 3094 per 100,000 persons) and increas-
ing mean cost per episode of disease (from $4247, to
$8789, to $16,775). The increase in mean cost per
episode is especially pronounced for cases of disease re-
quiring inpatient care ($18,224, $21,815, and $31,233
across risk groups), which correlates with longer mean
length of stay in hospital (12.8 days, 17.0 days, and
23.4 days, respectively). While a similar finding was ex-
pected for IPD, these results were not robust due to the
relatively small number of identified episodes. Remark-
ably, while at-risk persons with ≥2 conditions and high-
risk persons accounted for only 8 % of the population,
they were responsible for more than 50 % of total IPD/
PNE costs. In addition, among persons with at-risk con-
ditions, elevated costs increased in a graded and mono-
tonic fashion with the number of conditions present,
and rates and costs of PNE were particularly high among
persons with severe asthma and diabetes versus those
with less severe disease.
The pattern of increasing costs across increasing
levels of risk is similar to that observed in the above-
cited prior study of the burden of pneumococcal dis-
ease among older US adults [2]. Although the risk
categories considered in the two studies are similar,
Table 1 Rates of invasive pneumococcal disease and all-cause pneumonia among healthy, at risk, and high-risk persons (Continued)
All cause pneumonia
Age <18 years Age 18–64 years Age ≥65 years
Rate per 100 K Rate ratiosa (95 % CI) Rate per 100 K Rate ratiosa (95 % CI) Rate per 100 K Rate ratiosa (95 % CI)
Risk Group
Healthy 587 – 458 – 1874 –
At-Risk 1801 3.1 (3.0–3.1) 1652 3.6 (3.6–3.6) 5662 3.0 (3.0–3.0)
Alcoholism 501 0.9 (0.6–1.3) 2109 4.6 (4.5–4.7) 7400 3.9 (3.8–4.1)
Asthma 1718 2.9 (2.9–3.0) 2078 4.5 (4.5–4.6) 8570 4.6 (4.5–4.6)
Chronic heart disease 3699 6.3 (6.1–6.5) 2533 5.5 (5.5–5.6) 7100 3.8 (3.8–3.8)
Chronic liver disease 3910 6.7 (5.7–7.8) 3002 6.6 (6.4–6.7) 7742 4.1 (4.0–4.3)
Chronic lung disease 3488 5.9 (5.8–6.1) 4802 10.5 (10.4–10.6) 12,379 6.6 (6.6–6.7)
Chronic use of oral steroids 1080 1.8 (1.6–2.1) 1164 2.5 (2.5–2.6) 3696 2.0 (1.9–2.1)
Diabetes 808 1.4 (1.3–1.5) 1683 3.7 (3.6–3.7) 5266 2.8 (2.8–2.8)
Down’s syndrome 5514 9.4 (8.9–10.0) 2915 6.4 (5.6–7.3) 6316 3.4 (1.3–9.0)
Neuromuscular/seizure disorders 2536 4.3 (4.2–4.4) 2254 4.9 (4.8–5.0) 8539 4.6 (4.5–4.7)
Short gestation/low birthweight 2768 4.7 (4.6–4.8) 581 1.3 (1.1–1.5) 8864 4.7 (2.4–9.5)
Rheumatoid arthritis/Crohn’s/Lupus – – 2131 4.7 (4.6–4.7) 6465 3.5 (3.4–3.5)
Smokers 777 1.3 (1.0–1.8) 1858 4.1 (4.0–4.1) 6691 3.6 (3.5–3.6)
High-Risk 3757 6.4 (6.2–6.6) 3094 6.8 (6.7–6.8) 7594 4.1 (4.0–4.1)
Chronic renal failure 4202 7.2 (6.7–7.7) 5566 12.2 (12.0–12.3) 11,873 6.3 (6.3–6.4)
Cochlear implant 2062 3.5 (2.6–4.8) 1708 3.7 (2.8–5.0) 4544 2.4 (1.8–3.2)
Congenital immunodeficiency 4409 7.5 (7.0–8.0) 5919 12.9 (12.6–13.3) 14,738 7.9 (7.5–8.2)
Diseases of white blood cells 6048 10.3 (9.7–11.0) 6797 14.8 (14.6–15.1) 13,262 7.1 (6.9–7.3)
Functional/anatomic asplenia 8566 14.6 (13.9–15.3) 8721 19.0 (18.7–19.4) 15,976 8.5 (8.3–8.7)
HIV 2291 3.9 (2.8–5.5) 2457 5.4 (5.2–5.5) 6461 3.4 (3.2–3.8)
Immuno. conditions/drugs 3595 6.1 (5.9–6.4) 3146 6.9 (6.8–6.9) 7248 3.9 (3.8–3.9)
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Table 2 Costs and resource use per episode of invasive pneumococcal disease and all-cause pneumonia among healthy, at risk, and high-risk persons
Invasive pneumococcal disease All-cause pneumonia
<18 years 18–64 years ≥65 years <18 years 18–64 years ≥65 years




Mean $50,744 $448 $32,879 $51,695 $499 $43,349 $22,733 $605 $20,897 $12,130 $484 $3280 $18,224 $592 $4247 $12,587 $487 $7015
SD $82,620 $1540 $70,509 $84,974 $1148 $80,000 $28,405 $963 $27,876 $50,885 $717 $25,431 $37,336 $1043 $18,463 $26,113 $1141 $20,127
LOS (mean) 11.0 – – 12.2 – – 9.7 – – 7.6 – – 12.8 – – 11.4 – –
No. OP Visits (mean) – 1.1 – – 1.8 – – 2.8 – – 1.2 – – 1.4 – – 1.8 –
n 118 65 183 498 97 595 199 18 217 11,123 35,206 46,329 16,633 63,609 80,242 13,898 11,848 25,746
At-Risk
Cost
Mean $101,491 $500 $47,111 $46,000 $1531 $39,377 $29,781 $412 $27,472 $19,207 $550 $7659 $21,815 $599 $8789 $13,719 $503 $8472
SD $147,671 $927 $110,596 $64,018 $4362 $61,160 $93,161 $662 $89,765 $46,187 $792 $29,922 $46,562 $1073 $30,729 $26,672 $1461 $21,716
LOS (mean) 17.3 – – 11.1 – – 10.7 – – 12.7 – – 17.0 – – 14.8 – –
No. OP Visits (mean) – 1.2 – – 2.3 – – 2.3 – – 1.2 – – 1.4 – – 2.0 –
n 12 14 26 360 63 423 457 39 496 4007 6508 10,515 18,583 29,554 48,137 36,714 24,178 60,892
High-Risk
Cost
Mean $29,896 $128 $22,891 $45,406 $715 $42,985 $23,809 $1714 $21,674 $35,721 $612 $20,304 $31,233 $750 $16,775 $15,090 $571 $9495
SD $23,936 $83 $24,476 $52,315 $656 $51,872 $30,280 $4196 $29,536 $101,049 $925 $77,632 $62,950 $2477 $48,142 $26,296 $1745 $21,820
LOS (mean) 8.6 – – 12.5 – – 9.8 – – 18.5 – – 23.4 – – 16.7 – –
No. OP Visits (mean) – 1.0 – – 3.0 – – 4.0 – – 1.3 – – 1.6 – – 2.3 –
n 13 4 17 227 13 240 271 29 300 525 411 936 8480 7651 16,131 17,809 11,165 28,974















Fig. 1 a Annual cost of invasive pneumococcal disease per 100,000 healthy, at-risk, and high-risk persons. b Annual cost of all-cause pneumonia
per 100,000 healthy, at-risk, and high-risk persons
Fig. 2 a Annual cost of invasive pneumococcal disease per 100,000 persons with at-risk conditions – by number of conditions – versus their
healthy counterparts. b Annual cost of all-cause pneumonia per 100,000 persons with at-risk condition – by number of conditions – versus their
healthy counterparts
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direct comparisons of costs with the prior study are
challenging because they were estimated from different
sources and were presented in a different manner. In the
prior study, for example, direct costs of inpatient care
were estimated on the basis of reported charges for
the relevant conditions in the 2004 Healthcare Cost
and Utilization Project Nationwide Inpatient Sample
(HCUP NIS), after “stepping-down” costs to charges
using hospital-specific cost-to charge ratios. In the
current study, inpatient costs were estimated from paid
amounts available in healthcare claims. In the prior study,
costs were presented for the entire US population of older
adults (i.e., those aged ≥50 years) stratified into four age
groups, while in the current study costs were presented
per 100,000 adults aged 19–64 years and ≥65 years,
respectively.
Two additional findings merit further discussion. First,
rate and cost ratios for IPD and PNE were similar. This
finding likely is explained by two factors. The predomin-
ant manifestation of IPD is bacteremic pneumonia–69 %
of all cases in the US in 2012—and pneumococcus is
believed to be the leading bacterial cause of all-cause
pneumonia [8, 10]. Thus, to a considerable extent, these
two outcomes overlap and represent the same clinical
manifestation—pneumococcal pneumonia. In addition,
conditions that predispose to pneumonia caused by S.
pneumoniae may increase the risk of disease due to
other pathogens. For example, chronic lung disease
probably increases the risk of pneumonia caused by
influenza virus. The second finding was that rate ratios
were smaller in older persons. We believe this finding to
be a manifestation of the general decrease in immuno-
competence that occurs with advancing age and that
almost certainly diminishes the risk gradient between
“healthy” older adults and those with established chronic
medical conditions.
While healthcare claims databases provide information
on large numbers of patients with specific diagnoses and
the associated healthcare utilization, several limitations
from the use of such databases for our study should be
noted. First, use of operational algorithms and health-
care claims data resulted in an underestimation of the
incidence of IPD (e.g., ~8 per 100,000 children <5 years
of age) compared with national estimates from the
Centers for Disease Control and Prevention (e.g., ~20
per 100,000 children <5 years of age) [10]. For IPD, it is
likely that sometimes only the ICD-9-CM diagnosis code
for unspecified septicemia or bacteremia is recorded on
the healthcare claim form, without an accompanying
diagnosis code for pneumococcus. Thus, while such en-
counters would be correctly identified as invasive dis-
ease, they would not be correctly identified as IPD. In
addition, private healthcare claims databases—like the
ones used in this study—include information for com-
mercially insured populations, which often have an over-
all lower risk of disease. We note, however, that the age
distribution of IPD cases in our study is similar to the
distribution that has been reported by the Centers for
Fig. 3 Distribution of persons by risk profile and among at-risk persons by number of conditions (Panel a), distribution of pneumococcal disease
episodes among at-risk persons by number of conditions (Panel b), and distribution of pneumococcal disease costs among persons at-risk by
number of conditions (Panel c)
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Disease Control and Prevention (CDC). While it is not
possible to formally evaluate the accuracy of our case-
ascertainment algorithms within the context of this
study, we did evaluate the sensitivity of our study results
by employing alternative approaches to characterizing
risk profiles and individual conditions. In one approach,
relevant data available during the calendar year were
considered as evidence that such conditions were
present at the beginning of the calendar year, while in
another approach, such evidence was treated as a change
in risk status during the calendar year. Analyses also
were conducted using less restrictive (i.e., more sensi-
tive) algorithms in which any diagnostic, procedure, or
drug information was considered evidence that such
conditions were present. In addition, analyses were con-
ducted by individual calendar year, with varying dura-
tions of look-back to ascertain risk profiles (e.g., ≤1 year
for 2007, ≤4 years for 2010). Across all of the above-
described analyses, our findings were largely unchanged.
Second, persons with public or no health insurance
are not represented in the study databases, potentially
limiting the generalizability of study results to other
populations. Third, the costs of PNE are not a substitute
for the costs of pneumococcal pneumonia, and thus our
study undoubtedly overestimated the absolute clinical and
economic burden of pneumococcal disease. For this rea-
son, our study focused on rate ratios and cost ratios,
rather the rates and costs per se. Assuming that the costs
of pneumococcal pneumonia are similar to the costs of
pneumonia due to infection with other pathogens, the
costs of pneumococcal pneumonia would be proportional
to the percentage of all-cause pneumonia due to S. pneu-
moniae, recently estimated for community-acquired pneu-
monia at 27 % (95%CI 21–29) [8]. Fourth, this study
employed a retrospective cohort design and data from
three large integrated healthcare claims databases to
increase the precision of estimates. Although the three
study databases comprise information from unique health
plans and thus do not overlap at the plan level, it is pos-
sible that claims information from different time periods
for the same patient may appear in each extract (and can-
not be linked because of unique encrypted IDs). We
believe such occurrences to be rare and the potential
bias—if any—to be minimal. Finally, we did not include
data on pneumococcal vaccination status in our analyses
due to the lack of reliable information on this subject.
Several generic limitations of retrospective studies
based on healthcare claims data also should be noted.
All healthcare claims databases contain errors of omis-
sion and commission in coding, which undoubtedly
results in some misclassification of study outcomes. Cer-
tain biases in coding may exist such that patients who,
for example, are hospitalized for IPD or PNE may be
more likely to have selected underlying at-risk/high-risk
conditions listed as primary/secondary diagnoses on
their claims, all else equal. Moreover, information often
is not available for one or more clinically important
parameters (in our study, for example, blood glucose/
glycated hemoglobin [HbA1c] for diabetes, ejection
fraction/New York Heart Association [NYHA] Class for
heart failure), and pertinent medical history can be left-
censored (e.g., diagnoses recorded before the time period
of the study database are unobservable). The impact of
these limitations on our results cannot be assessed
within the scope of this study.
Conclusion
In conclusion, the results of this study demonstrate that
rates and costs of pneumococcal disease remain dispro-
portionately high in persons with at-risk and high-risk
conditions in the current era of widespread pneumococ-
cal vaccination. Study results also demonstrate that rates
and costs for individuals with ≥2 at-risk conditions
approached those among persons with high-risk condi-
tions, and that the rates and costs for persons with
asthma and diabetes were especially increased.
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